Reference is made to the announcements of Fosun International Limited (the "Company") dated 4 October 2012, 16 October 2012 and 17 October 2012 in relation to the proposed issue and listing of H shares of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"), a subsidiary of the Company and whose A shares are listed and traded on the Shanghai Stock Exchange (Stock Code: 600196), on The Stock Exchange of Hong Kong Limited (the "Hong Kong Stock Exchange").

The board of directors of the Company would like to update the shareholders of the Company and the public investors that Fosun Pharma has issued the announcement of allotment results dated 29 October 2012, pursuant to which the offer price has been determined at HKD11.80 per H share, plus brokerage of 1%, Securities and Futures Commission transaction levy of 0.003% and Hong Kong Stock Exchange trading fee of 0.005%.

Based on the offer price of HKD11.80 per H share, the net proceeds from the global offering to be received by Fosun Pharma, after deduction of the underwriting commissions and other estimated expenses payable by Fosun Pharma in the global offering and assuming no exercise of the over-allotment option, is estimated to be approximately HKD3,764.4 million. It is expected that Fosun Pharma will list its H shares on the Main Board of Hong Kong Stock Exchange with stock code 02196 on 30 October 2012.

By Order of the Board
Fosun International Limited
Guo Guangchang

Shanghai, the PRC, 29 October 2012